Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
Open Access
- 1 September 1990
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 86 (3) , 851-855
- https://doi.org/10.1172/jci114784
Abstract
Human ovarian cancer, the leading cause of death from gynecologic malignancy, tends to remain localized to the peritoneal cavity until late in the disease. In established disease, ascitic fluid accumulates in the peritoneal cavity. We have previously demonstrated that this ascitic fluid is a potent source of in vitro mitogenic activity including at least one unique growth factor. We now report that the human ovarian adenocarcinoma line, HEY, can be induced to grow intraperitoneally in immunodeficient nude mice in the presence (23/28 mice), but not absence (0/21 mice) of ascitic fluid from ovarian cancer patients. Ascitic fluid from patients with benign disease did not have similar effects on intraperitoneal growth of HEY cells (1/15 mice). Once tumors were established by injections of exogenous ascitic fluid, they could progress in the absence of additional injections of ascitic fluid. The mice eventually developed ascitic fluid which contained potent growth factor activity, suggesting that the tumors eventually produced autologous growth factors. This nude mouse model provides a system to study the action of ovarian cancer growth factors on tumor growth in vivo and to evaluate preclinically, therapeutic approaches designed to counteract the activity of these growth factors.This publication has 9 references indexed in Scilit:
- A PUTATIVE NEW GROWTH-FACTOR IN ASCITIC FLUID FROM OVARIAN-CANCER PATIENTS - IDENTIFICATION, CHARACTERIZATION, AND MECHANISM OF ACTION1988
- Characterization of binding of four monoclonal antibodies to the human ovarian adenocarcinoma cell line HEYBiochemistry and Cell Biology, 1987
- MONOCLONAL-ANTIBODIES TO AN EPITHELIAL OVARIAN ADENOCARCINOMA - DISTINCTIVE REACTIVITY WITH XENOGRAFTS OF THE ORIGINAL TUMOR AND A CULTURED-CELL LINE1986
- In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.The Journal of Immunology, 1985
- Common Epithelial Cancer of the OvaryNew England Journal of Medicine, 1985
- Common Epithelial Cancer of the OvaryNew England Journal of Medicine, 1985
- Autocrine growth factors and cancerNature, 1985
- COMPARATIVE PROPERTIES OF 5 HUMAN OVARIAN ADENOCARCINOMA CELL-LINES1985
- THE MOLECULAR GENETICS OF CELLULAR ONCOGENESAnnual Review of Genetics, 1984